Hayfin Capital Management Supplies $400MM Debt Financing to Amicus Therapeutics
Hayfin Capital Management executed a $400 million credit facility for Amicus Therapeutics, a biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases.
July 17, 2020
Amicus Therapeutics | Daphne Quimi | Hayfin Capital Management | Howard Rowe | John F. Crowley
Phil Neuffer